Long-term central venous catheter use and risk of infection in older adults with cancer.

PURPOSE Long-term central venous catheters (CVCs) are often used in patients with cancer to facilitate venous access to administer intravenous fluids and chemotherapy. CVCs can also be a source of bloodstream infections, although this risk is not well understood. We examined the impact of long-term CVC use on infection risk, independent of other risk factors such as chemotherapy, in a population-based cohort of patients with cancer. PATIENTS AND METHODS We conducted a retrospective analysis using SEER-Medicare data for patients age > 65 years diagnosed from 2005 to 2007 with invasive colorectal, head and neck, lung, or pancreatic cancer, non-Hodgkin lymphoma, or invasive or noninvasive breast cancer. Cox proportional hazards regression was used to examine the relationship between CVC use and infections, with CVC exposure as a time-dependent predictor. We used multivariable analysis and propensity score methods to control for patient characteristics. RESULTS CVC exposure was associated with a significantly elevated infection risk, adjusting for demographic and disease characteristics. For patients with pancreatic cancer, risk of infections during the exposure period was three-fold greater (adjusted hazard ratio [AHR], 2.93; 95% CI, 2.58 to 3.33); for those with breast cancer, it was six-fold greater (AHR, 6.19; 95% CI, 5.42 to 7.07). Findings were similar when we accounted for propensity to receive a CVC and limited the cohort to individuals at high risk of infections. CONCLUSION Long-term CVC use was associated with an increased risk of infections for older adults with cancer. Careful assessment of the need for long-term CVCs and targeted strategies for reducing infections are critical to improving cancer care quality.

[1]  M. Gorman,et al.  Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Susan S. Huang,et al.  Discord among Performance Measures for Central Line—Associated Bloodstream Infection , 2013, Infection Control & Hospital Epidemiology.

[3]  A. Matlow,et al.  Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Armstrong,et al.  Infections in Patients with Cancer: Overview , 2011, Principles and Practice of Cancer Infectious Diseases.

[5]  K. Sepkowitz,et al.  Nosocomial infections in patients with cancer. , 2009, The Lancet. Oncology.

[6]  S. Saint,et al.  Executive Summary: A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals , 2008, Infection Control & Hospital Epidemiology.

[7]  Y. Yazdanpanah,et al.  Risk factors for early catheter‐related infections in cancer patients , 2007, Cancer.

[8]  Dan M. Kluger,et al.  The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. , 2006, Mayo Clinic proceedings.

[9]  S. Coffin,et al.  Administrative Data Fail to Accurately Identify Cases of Healthcare-Associated Infection , 2006, Infection Control & Hospital Epidemiology.

[10]  Richard Platt,et al.  Administrative Databases Provide Inaccurate Data for Surveillance of Long-Term Central Venous Catheter-Associated Infections , 2003, Infection Control & Hospital Epidemiology.

[11]  Sanjay Saint,et al.  Guidelines for the prevention of intravascular catheter-related infections. , 2002, American journal of infection control.

[12]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[13]  K. Sepkowitz,et al.  Complication rates among cancer patients with peripherally inserted central catheters. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[15]  Gregory S. Cooper,et al.  Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.

[16]  G. Cooper,et al.  Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.

[17]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[18]  T. Brennan,et al.  Incidence and types of preventable adverse events in elderly patients: population based review of medical records , 2000, BMJ : British Medical Journal.

[19]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[20]  P. Kearns Infectious morbidity associated with long-term use of venous access devices in patients with cancer. , 1994, JPEN. Journal of parenteral and enteral nutrition.

[21]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[22]  E. V. van Pampus,et al.  Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.